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Abstract
CTNND1 encodes the p120-catenin (p120) protein, which has a wide range of functions, including the maintenance of
cell–cell junctions, regulation of the epithelial-mesenchymal transition and transcriptional signalling. Due to advances in
next-generation sequencing, CTNND1 has been implicated in human diseases including cleft palate and
blepharocheilodontic (BCD) syndrome albeit only recently. In this study, we identify eight novel protein-truncating variants,
six de novo, in 13 participants from nine families presenting with craniofacial dysmorphisms including cleft palate and
hypodontia, as well as congenital cardiac anomalies, limb dysmorphologies and neurodevelopmental disorders. Using
conditional deletions in mice as well as CRISPR/Cas9 approaches to target CTNND1 in Xenopus, we identified a subset of
phenotypes that can be linked to p120-catenin in epithelial integrity and turnover, and additional phenotypes that suggest
mesenchymal roles of CTNND1.We propose that CTNND1 variants have a wider developmental role than previously
described and that variations in this gene underlie not only cleft palate and BCD but may be expanded to a broader
velocardiofacial-like syndrome.
Introduction
Genetic variation in CTNND1, which encodes for the armadillo-
repeat protein p120-catenin (p120), is associated with human
birth defects, most notably non-syndromic cleft palate and ble-
pharocheilodontic (BCD) syndrome, which involves eyelid, lip
and tooth anomalies [MIM: 617681] (1–3). In contrast, experi-
ments in animal models have suggested broader developmental
roles for CTNND1. For example, conditional deletions in mice
demonstrate the importance of CTNND1 for development not
only for skin and teeth but also for kidneys and other struc-
tures (4–10), and the complete deletion of CTNND1 leads to
prenatal lethality (5,9). Similarly, loss-of-function experiments in
Xenopus implicate CTNND1 in craniofacial development (11,12).
Here, we describe a series of patients with CTNND1 variants, all
of whom present with multisystem involvement that demon-
strates a broad spectrum craniofacial and cardiac syndrome.
p120-catenin is a member of the catenin superfamily of pro-
teins studied in catenin–cadherin interactions; notably, it binds
to and stabilizes E-cadherin (CDH1) at junctional complexes in
epithelia (13–17). This binding is via the p120-catenin armadillo
repeat domain, and the displacement of p120-catenin from E-
cadherin is a key regulatory event at the adherens junction,
which results in the endocytosis of E-cadherin and loss of the
junction. The protein has a second function as a scaffolding
protein for the GTPase RhoA and associated Rho regulatory
proteins (18,19). In addition, it can also directly interact with
the zinc finger transcriptional repressor Kaiso (ZBTB33), facilitat-
ing Wnt signal transduction (20,21). Thus, p120-catenin appears
to be a multi-functional protein, promoting epithelial stability
when in complex with E-cadherin and regulating RhoA and
transcriptional activities. p120-catenin is also able to associate
with mesenchymal cadherins such as N-cadherin and cadherin-
11 (17,22). In mesenchymal cells, p120-catenin associates with
non-epithelial cadherins, regulating motility and invasion via
cytoskeletal events and transcription. Given its functions in both
epithelia and mesenchyme, it is unsurprising that both the loss
and gain of p120-catenin have been associated with oncogenesis
(23–25).
In humans, the CTNND1 gene is located at 11q11 and consists
of 21 exons; of which, exons 11, 18 and 20 are alternatively
spliced. Inclusion of exon 11, which is predominantly neural,
disrupts a nuclear localization signal, while exon 20 contains a
nuclear export signal (26). In addition, there are four additional
isoforms of the protein, which vary in their transcriptional start
sites. Of the four major isoforms, isoform 1 is abundant in mes-
enchymal cells,while isoform 3 appears preferentially expressed
in epithelial cells (27–30). The other two isoforms are less well
characterized.
The p120 superfamily includes p120-catenin itself, δ-catenin
(CTNND2) and ARVCF [armadillo repeat gene deleted in velo-
cardiofacial (VCF) syndrome] all of which can compete for E-
cadherin binding. Although it is unclear whether they substitute
for one another in other cellular functions (31,32), evidence
from animal studies suggests some compensatory roles. For
instance, δ-catenin (CTNND2) knockdown phenotypes can be
rescued with p120-catenin, and the combined depletion of δ-
catenin and p120 generates more pronounced effects. However,
levels of p120 are not altered by reducing δ-catenin protein
levels (33). In humans, CTNND2 variants have been associated
with autism spectrum disorders and other neurodevelopmental
conditions (34–39). Interestingly, the other p120 family mem-
ber, ARVCF, lies in 22q11. While the loss of TBX1 in 22q11 is
thought to cause the key malformations associated with VCF
syndrome [MIM: 192430], evidence from animal models suggests
that ARVCF may also play a role in craniofacial development
(40–43).
Here, we present a multi-system condition beyond that
described in known p120-associated cases, which was recently
described in the context of BCD (1–3). However, the majority
of reported BCD cases are caused by E-cadherin variation (1–
3). While our subjects possess palatal phenotypes and eyelid
anomalies, they also consistently display additional features
including cardiac, limb and neurodevelopmental anomalies.
Only a subset of our participants had eyelid symptoms, and
none were diagnosed with BCD prior to genetic analysis.
Therefore, we propose that these novel truncating variants in
CTNND1 should be considered to be a phenotypic expansion
beyond BCD. Furthermore, we propose that these variants affect
both E-cadherin-dependent and -independent functions of
p120-catenin and, given the range of phenotypes seen in our
cohort, should be considered more broadly to cause a VCF-like
syndrome.
Subjects and Methods
Recruitment, consent and sample collection
Participantswere recruited from one of following: South Thames
Cleft Unit at Guy’s and St Thomas Trust (GSTT), London, UK; the
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University of Calgary, Alberta Children’s Hospital, Canada;
the Children’s Hospital of Philadelphia, USA; or the Deci-
phering Developmental Disorders (DDD) Study, UK (www.
ddduk.org). CTNND1 data access was specifically collected
under DDD Project CAP180, focusing on cranial neural crest
anomalies (ABM/KJL). All individual study protocols were
approved by local Institutional Review Boards, including UK
Ethics: GSTT (REC16/NI/0026, Northern Ireland REC) and DDD
(10/H0305/83, Cambridge South REC, and GEN/284/12, Republic
of Ireland REC).
Medical and dental histories were taken, as well as
detailed phenotyping by clinical geneticists with expertise
in dysmorphology. Saliva for DNA extraction was collected
from family trios using the Oragene® DNA (OG-500) kit.
All patients also underwent high-resolution analysis for
copy number abnormalities using array-based comparative
genomic hybridization. Informed consent from all participants
was obtained for the publication of data and photographs
in the medical literature. All families were offered genetic
counseling.
Whole exome sequencing and variant screening
Whole exome sequencing (WES) from trios was performed
to identify gene variants. For patients recruited from DDD
(44), genomic DNA samples from trios were analysed at the
Wellcome Trust Sanger Institute. WES was performed using a
custom Agilent SureSelect Exome bait design (Agilent Human
All Exon V3 Plus with custom ELID # C0338371), 8-plex sample
multiplexing and an Illumina HiSeq with four samples per
lane and a mean depth of 50X. The exome analysis targeted
58.62 Mb of which 51.64 Mb consisted of exonic targets (39 Mb)
and their flanking regions and 6.9 Mb consisted of regulatory
regions. Alignment was performed using BWA1. Putative de novo
variants were identified from trio BAM files using DeNovoGear5.
Variants were annotated with the most severe consequence
predicted by Ensembl Variant Effect Predictor (VEP version 2.6),
and minor allele frequencies from a combination of the 1000
Genomes project (www.1000genomes.org), UK10K (www.uk10
k.org), the NHLBI Exome Sequencing Project (esp.gs.washingto
n.edu), Scottish Family Health Study (www.generationscotland.o
rg), UK Blood Service and unaffected DDD parents. All flagged
variants were automatically annotated with pathogenicity
scores from two variant prioritization algorithms (SIFT23 and
PolyPhen24) and compared against the public Human Gene
Mutation Database and the Leiden Open Variation Database.
For selected probands, WES performed at the Yale Center for
Genomic Analysis used genomic DNA isolated from saliva
from the probands and their parents. The exons and their
flanking regions of the genome were captured using IDT
xGen exome capture kit followed by Illumina DNA sequencing
(HiSeq 4000). Paired end sequence reads were converted to
FASTQ format and were aligned to the reference human
genome (hg19). GATK best practices were applied to identify
genetic variants, and variants were annotated by ANNOVAR.
Probands and parents were sequenced to a mean depth of
93–123 independent reads per targeted base across all the
samples. In an average of 94.0% of targeted bases in all of
the samples, the coverage was greater than 20X independent
reads. Trio WES analysis on variants with allele frequency of
less than 1% was carried out to identify de novo variants that are
absent from the parents. Putative disease-causing variants were
validated using whole genome amplified DNA, PCR and capillary
sequencing.
Mouse and Xenopus husbandry
Animal work was performed in accordance with UK Home
Office Project License P8D5E2773 at King’s College London (KJL),
University of Texas Southwestern Medical Center Institutional
Animal Care and Use Committee protocols (DKM), the European
Xenopus Resource Centre, Portsmouth UK, or the Yale University
Institutional Animal Care and Use Committee protocols (MKK).
Mice were genotyped according to standard procedures.
Gestational ages for mice were determined by the observation
of vaginal plugs, which was considered embryonic day 0.5 (E0.5)
and further staging of animals according to Kaufman (45). The
following mouse strains were used: Ctnnd1fl/f l (MGI ID: 3640772)
(8); β-actin::cre (JAX strain 019099) (46) and Wnt1::cre (JAX strain
022501) (47).For eachmouse experiment, aminimumof n=3was
examined unless otherwise noted. Xenopus tropicalis embryos
were produced by in vitro fertilization and raised to appropriate
stages in 1/9MR+gentamycin as per standard protocols (48).
For Xenopus experiments, experimental numbers are stated in
figures,with aminimum of n=30 in all experimental conditions.
Human specimens
Human embryonic and fetal material was provided by the
Joint MRC/Wellcome Trust (Grant #099175/Z/12/Z) Human
Developmental Biology Resource (HDBR,http://www.hdbr.org) as
whole embryos [Carnegie stage 13 (C13, day 28–32)] or sectioned
embryos [Carnegie stage 21 (C21, day 50–52)].
Generation of CTNND1 probe and mRNA
in situ hybridization
A human CTNND1 clone was identified from the Human
ORFeome Collaboration (49) (clone HsCD00513511), encoding
CTNND1 isoform 4, including the entirety of the armadillo
repeats and the C-terminal domain. Probes made from this
clone should recognize all fourCTNND1 transcripts.Digoxigenin-
labeled antisense mRNA probes were produced by linearizing
human CTNND1 clones using BamH1 restriction enzyme, which
produces a probe size of ∼900 base pairs, and in vitro transcrip-
tion with the T7 High Yield RNA Synthesis Kit (E2040S) from
New England Biolabs. In situ hybridization of mRNA on whole
mount and paraffin embedded tissue sectionswas carried out as
per standard protocols (50), using an anti-digoxigenin-alkaline
phosphatase coupled antibody.
Immunofluorescent antibodies and staining
For immunostaining, mouse embryos at the indicated stages
were fixed and processed according to standard protocols.
Antigen retrieval was carried out in Tris-EDTA (pH 9) in a
90◦C water-bath for 30 min. Primary antibodies used were:
phospho-tyrosine p120-catenin clone 2B12, mouse mAb (1:150,
Biolegend, Cat. No. 828301); delta 1 Catenin/CAS (phospho S-
268) antibody [EPR2380], rabbit mAB (1:150, Abcam, Cat. No.
ab79545); E-Cadherin [M168], mouse mAB (1:150, Abcam, Cat.
No. ab76055); anti-E-cadherin (24E10), rabbit mAb (1:250, Cell
Signaling Technology, Cat. No. 3195); rabbit anti-Pax2 Antibody
(1:100, ThermoFisher Scientific, Cat. No. 71-6000) and mouse
anti-Collagen Type II, clone 6B3 (1:50, MERCK, Cat. No.MAB8887).
Secondary antibodies used were: Alexa Fluor® 488 (Invitrogen,
A-11008), Alexa Fluor® 488 (Invitrogen, A-21204), Alexa Fluor®
546 (Invitrogen, A-11060), Alexa Fluor® 568 (Invitrogen, A-11011),
Alexa Fluor® 594 (Invitrogen, A-21207) and Alexa Fluor® 647
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(Invitrogen, A-21235). All were diluted to 1:400 in phosphate-
buffered saline (PBS) containing 0.5% Triton® X-100 (Sigma-
Aldrich) and 1% bovine serum albumin. Slides were mounted
in Fluoroshield Mounting Medium with DAPI (Abcam, ab104139)
and cover slipped. Xenopus whole mount embryos and tadpoles
were incubated with Hoechst (1:5000 of 20 mg/ml, diluted in
PBST). For hematoxylin and eosin (H&E) staining, slides were
fixed, sectioned and stained according to standard protocols.
Slides were then cover slipped with Neo-Mount (VWR, Cat. No.
1.09016.0500).
Image acquisition
Images for sectional in situ hybridization experiments and for
H&E slides were captured using a brightfield microscope (Nikon
ECLIPSE Ci-L), with an attached camera (Nikon digital sight DS-
Fi1) or with a NanoZoomer 2.ORS Digital Slide Scanner (Hama-
matsu); NDP.view2 Viewing Software (U12388-01) was used to
analyze the scanned images. Whole mount images of mouse
pups and embryos, Xenopus and human embryos were captured
using a Nikon SMZ1500 stereomicroscope with a Nikon digi-
tal sight DS-Fi1 (112031) camera. Fluorescent images of mouse
palates and Xenopus epithelial cells were either acquired on
a Leica SP5 confocal or Nikon A1R point scanning confocal;
z-stacks of whole mount Xenopus tadpoles were captured by
mounting the tadpoles on a Cellview Cell Glass Bottom Cul-
ture Dish (PS, 35/10 mm, CELLviewTM, Cat. No. 627860) in PBS.
Image sequences were processed using the FIJI (Image J) analysis
software.
Micro-computed tomography
For soft tissue scanning, mouse embryos were stained with a
near isotonic 1% I2 and 2% potassium iodine solution for 3 days
and scanned to produce 6 μm voxel size volumes, using X-ray
settings of 90 kVp, 66 uA and a 0.5 mm aluminium filter to
attenuate harder X-rays. Camera binning was used to improve
signal-to-noise ratios. For hard tissue staining, perinatal mice
were scanned to produce 7.4 μm voxel size volumes using X-
ray settings of 70 kVp, 114 uA and a 0.5 mm aluminium fil-
ter to attenuate harder X-rays. The specimens were analysed
using Parallax Microview software package (Parallax Innova-
tions Inc., Ilderton, ON, Canada). Specimens were scanned using
a Scanco μCT50 microcomputed tomographic (μCT) scanner
(Scanco, Brüttisellen, Switzerland). The specimens were immo-
bilised in appropriately sized scanning tubes using cotton gauze.
CRISPR/Cas9 knockouts in X. tropicalis
The following non-overlapping single guide RNAs (sgRNAs) were
designed to target X. tropicalis ctnnd1: sgRNA1—CTAGCtaatacgact
-cactataGGAACGGGTGTGGGAGCCATgttttagagctagaa and sgRNA
-2—CTAGCtaatacgactcactataGGGGTGGTATCCCACGCAAGgttttaga
-gctagaa. sgRNA1 targets exon 3 and is thus predicted to disrupt
isoform 1 only,while sgRNA2 targets exon 7 and is thus predicted
to disrupt all four isoforms. Embryos were injected at the one- or
two-cell stage and raised until indicated stages. For CRISPR/Cas9
experiments, statistical significance was defined as P<0.05 and
analysed by chi-squared test or Fisher’s exact test.
Results
Identification of CTNND1 variants
Here, we identify 13 individuals from nine families with novel
protein-truncating variants in CTNND1. These mutations were
not previously described in BCD, orofacial cleft cases nor in
gnomAD (Table 1). Family trees are shown in Figure 1A, while
mutations from this study and from previous studies have
been mapped onto a protein schematic (Fig. 1B). Notably, two
unrelated individuals had the same novel (p.Arg461∗) variant we
describe here (Fig. 1). Previously, all subjects had undergone an
array-based comparative genome hybridization analysis with
normal results. A subset of participants had also been referred
for other diagnostic tests, including 22q11 deletion, Down
syndrome, CHARGE syndrome (CHD7 sequencing), Noonan
syndrome (PTPN11 sequencing) and other conditions, but with
no definitive diagnoses. WES of the nine families revealed eight
novel variants in CTNND1, including six confirmed to have
arisen de novo (in eight patients). Two individuals inherited
their variant from affected parents, while two other participants
inherited a variant from a parentwith amild phenotype (Fig. 1A).
These truncating mutations included nonsense, splicing and
frameshift variants (Table 1).
CTNND1 variants identified could be grouped according
to the overall structure of the protein (Fig. 1B). Beginning
with the N-terminal regulatory region, one variant falling
within this region was identified in a mother (Patient 1)
and later confirmed in her affected daughter by targeted
sequencing (Patient 2). The mother’s de novo CTNND1 variant
is designated as c.443_444delTG (p.Val148Aspfs∗24) affecting
exon 6.
Four variants fell within the armadillo repeats, which are
predicted to be crucial for interactions with E-cadherin. Two
unrelated individuals (Patients 3 and 4) from two different
families had the same de novo mutation in CTNND1: c.1381C>T
(p.Arg461∗) (Fig. 1A and B). This variant results in a non-sense
substitution and creates a stop codon in exon 7. In addition,
Patient 3 had a rare variant in CTNND1, inherited paternally
c.943C>T (p.Arg315Cys), which is present at a frequency of
2×10–4 in reference populations (51). As the parent shares
none of the phenotypes with the patient, this second variant is
unlikely to be causative. Moreover, a CTNND1 frameshift variant
c.1481_1485del (p.Leu494Argfs∗5) in exon 8 was identified
in a mother and child; both are affected (Patients 6 and 7,
respectively); however, the de novo status in the mother had
not been confirmed. In the same exon, Patient 8 had a de
novo CTNND1 variant designated as c.1594del (p.Gly532Alafs∗6).
Finally, a de novo mutation in armadillo 9 was found in Patient 5
designated as c.2389C>T (p.Arg797∗) on exon 15.
We found three variants affecting the C-terminal domain,
whichwere present in five patients in three families. The variant
c.2598_2601dupTGAT (p.Ser868∗) was paternally inherited in a
family with two affected siblings (Patients 9 and 10). Anecdotally,
the father is fit and healthy; however, his palate is narrow and
high, and his nose is prominent; his de novo status has not been
confirmed. Patient 11 has a de novo CTNND1 variant at the splice
acceptor site of exon 19 designated as c.2702-5A>G, which is
predicted to create a cryptic splice site, leading to a premature
termination codon at the start of exon 19. Finally, Patients 12 and
13 are monozygotic twins carrying a de novo frameshift variant
in CTNND1: c.2737dupC (p.His913Profs∗3).
Clinical presentation of patients with CTNND1 variants
Clinical phenotypes are summarized in Table 2, and further
details can be found in Supplementary Material, Table S1.
Also included in Supplementary Material, Table S1 are the
summaries of phenotypes seen in previous reports (1,2).
Photographs from participants show a number of shared
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Figure 1. Pedigrees and identification of CTNND1 variants. (A) Pedigrees of individuals with identified variants. Family identifications, in brackets [A-I], and patient
identification numbers correlate with Table 1. Filled boxes indicate affected individuals demonstrating collective phenotypes described in our cohort. A blank box with
a vertical black line indicates an asymptomatic carrier (clinically unaffected). A box with an oblique line indicates a deceased individual. Lightly shaded boxes indicate
individuals affected with one or more of the conditions described. (B) Schematic representation of the human p120-catenin protein structure and its domains. The
variants described in our cohort are shown above the protein with a dark gray arrow. The light gray arrow with the (p.Arg315Cys) variant indicates the other CTNND1
mutation found in Patient 3 which was inherited from the unaffected father [A]. Arrows in blue, pink and brown represent the variants and their locations reported in
Ghoumid et al. (2), Kievit et al. (1) and Cox et al. (3), respectively.
craniofacial and oral features (Figs 2 and 3, respectively)
as well as other affected structures [eyes, ears and limbs
(Supplementary Material, Figure S1)].Additional features includ-
ing heart anomalies and neurodevelopmental conditions are
noted in Table 2 and Supplementary Material, Table S1.
Participants shared several distinctive eye features includ-
ing short, up-slanted palpebral fissures (9/13), hooded eyelids
(8/13), telecanthus (7/13), highly arched (8/13) and thin lateral
eyebrows (8/13) and other eyelid anomalies such as nasolacrimal
obstructions (1/13). These eye anomalieswere clear froma young
age (Supplementary Material, Figure S1A). A subset had ectro-
pion (drooping lower eyelids, 4/13) and distichiasis (double eye-
lashes, 4/13). Many individuals had wide nasal bridges (11/13)
with broad nasal tips (7/13), choanal atresia (4/13), either unilat-
eral or bilateral atresia; malar flattening (mid-face hypoplasia)
(9/13); mandibular prognathism (5/13); thin upper lips (7/13)
and auricular abnormalities (9/13), particularly low-set ears and
overfolded helices (Supplementary Material, Figure S1B).
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Figure 2. Clinical presentation of individuals with a CTNND1 mutation. Facial photos (frontal and profile) show craniofacial features of patients. Note the narrow
up-slanting palpebral fissures in Patients 3, 4 and 7–13; the hooded eyelids in Patients 3, 4 and 8–13; telecanthus in Patients 3, 4 and 9–13; the high arched eyebrows in
Patients 1, 2, 6–8 and 11–13 and the thin lateral eyebrows in Patients 1 and 5–11. Patients 1 and 4 had missing eyelashes medially from the inner canthus; Patients 1,
2, 5 and 7 have distichiasis (double row of lashes), and mild ectropion of the lower eyelids was seen in Patients 1, 5 and 6. As evident, no patient shows signs of hair
sparsity. Most patients had wide nasal bridges with broad nasal tips, while Patients 1, 2, 8 and 11 were also diagnosed with congenital choanal atresia. Patients 1, 2,
7–9, 11 and 12 showed thin upper lips, and while mid-face hypoplasia was observed, Patients 1, 3, 8, 11 and 13 also had mandibular prognathism. Scars from cleft lip
operations are seen in Patients 7 and 9–13. Patient 3 was born with a sub-mucous cleft palate, a bifid uvula and VPI.
Phenotypes with high penetrance involved oropharyngeal
abnormalities including cleft lip and/or palate (CLP) (8/13),
high-arched palate (7/13) or a combination of cleft and high-
arched palate (Fig 3A–D). A range of cleft sub-types was seen
(Supplementary Material, Table S1). In addition, one participant
had velopharyngeal insufficiency (VPI) and a bifid uvula. Of
interest, three individuals presented with vocalization defects
causing stridor and hoarseness or nasal speech.
Upon dental examination, all subjects were found to
have intra-oral anomalies (Fig. 3). In particular, congenital
tooth agenesis (hypodontia) was frequently seen, with eight
subjects missing between 3 and 12 adult teeth (Fig. 3G–L;
Supplementary Material, Table S2). Other anomalies included
retained primary teeth and delayed eruption of the permanent
teeth (6/13) (Supplementary Material, Table S1). Morphologic
tooth anomalies were present, including diminutive permanent
teeth/peg-shaped lateral incisors and fissured crowns of
the permanent central and lateral incisors (Fig. 3E and F;
Supplementary Material, Table S1).
Beyond the craniofacial structures, the majority of the
participants had limb and heart anomalies. Mild limb phe-
notypes (9/13) were present, including shorter fifth fingers,
single transverse palmar crease, mild syndactyly between
the 2 and 3 toes, sandal gaps and camptodactyly of the
toes (Supplementary Material, Figure S1C). Congenital cardiac
defects, which have not previously been associated with
CTNND1 variants, consistently occurred in our cohort. Six
subjects had cardiovascular anomalies including tetralogy
of Fallot, hypoplastic aortic arch, coarctation of the aorta,
ventricular septal defect, atrial septal defect, mitral valve
stenosis, patent ductus arteriosus and patent foramen ovale
(Table 2; Supplementary Material, Table S1). Finally, in addition
to the craniofacial and cardiac anomalies, individuals presented
with other phenotypes that added to the complexity of their
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Figure 3. Dental manifestations and intra-oral phenotypes of patients with a CTNND1 mutation. (A–D) A high-arched palate was seen, shown are palates of Patients
1, 2, 3 and 8. (E, F) Abnormalities in the morphology of the dentition included: fissured incisors in patient 11 (E, black arrowheads) and rotation of the incisors from the
normal alignment shown in the non-cleft Patient 1 (F, black arrowhead). (G, H) Hypodontia (tooth agenesis) was a common phenotype, indicated by the black asterisk.
Black arrowheads indicate retained primary teeth. Patient 3 also has a diminutive upper left lateral incisor (G, yellow arrowhead) and wide inter-dental spacing (G′,
white arrowheads). (I–L) Dental orthopantograms (OPGs); missing teeth are indicated by white asterisks; diminutive teeth by yellow, macrodont teeth by magenta and
supernumerary teeth by blue arrowheads, respectively. (I) OPG of Patient 8 at age 11 shows eight missing permanent teeth (white asterisks) and shows the eruption
of the second permanent molars (white arrowheads) in place of the missing first permanent molars. Also shown are diminutive upper right and left lateral incisors
(peg-shaped) (yellow arrowheads) and a macrodont lower left second primary molar (magenta arrowhead). (J) OPG of Patient 11, at the age of 14, shows three missing
permanent teeth (white asterisks), an ectopic maxillary left permanent canine and rotated maxillary centrals and left lateral incisors and dilacerated roots of the
lower second permanent molars. (K) OPG of Patient 2, taken at 4 years, shows missing teeth including a missing lower left first permanent molar (white asterisks); a
reported macrodont upper left primary canine (magenta arrowhead) with an underlying missing successor (white asterisk); a macrodont lower left second primary
molar (magenta arrowhead) and a supernumerary tooth (blue arrowhead). (L) OPG for Patient 13, taken at 7.5 years, confirms the absence of the upper left permanent
lateral incisor and possibly the lower second permanent premolars.
conditions.Developmental delay and other neurodevelopmental
problems were also observed (8/13). These often appeared from
early toddler and school years and included mild learning diffi-
culties, autism spectrum disorder, speech and language delay
and behavioral problems (Supplementary Material, Table S1).
One individual was diagnosed with ovarian dysgerminoma
stage III in the left ovary at the age of 12 years, which
was treated with left oophorectomy followed by chemother-
apy. Other infrequent anomalies included urogenital prob-
lems, scoliosis and partial agenesis of the corpus callosum
(Supplementary Material, Table S1).
CTNND1 is expressed during human embryonic
development
CTNND1 has recently been linked to non-syndromic cleft palate
(3). In that study, Cox et al. (3) documented the protein distribu-
tion of human p120-catenin protein, focusing on the fusion of
the secondary palate. However, to our knowledge, little is known
about human CTNND1mRNAexpression during pharyngeal arch
stages. Given the multi-system anomalies seen in our subjects,
it was important to examine expression at earlier stages during
the development of the cranio-cardiac structures. Therefore, we
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Figure 4. P120-catenin is expressed during relevant stages of human embryonic development. CTNND1mRNA in situ hybridization at human Carnegie stages 13 (CS13)
(A–C) and 21 (D–G). (A) Right lateral view of a CS13 human embryo, CTNND1 mRNA is strongly expressed in the head in all three pharyngeal arches (PA1, PA2 and
PA3) and limb buds. Expression is specifically strong around the nasal placode and the maxillary and mandibular prominences. (B) Left lateral view, P120 is strongly
expressed in the developing heart, frontonasal process, the trigeminal ganglion and the tenth cranial nerve. (C) P120 is ubiquitously expressed in the developing brain
region in the rhombomeres, the forebrain and midbrain. (D–G) Coronal section through the head of a CS21 human embryo through a mid-palatal plane. (D) Strong
expression is seen in the intrinsic muscles of the tongue: the superior longitudinal (magenta arrowhead), the transversal muscles of the tongue (black arrowhead) and
the extrinsic genioglossus muscle (blue arrowhead). (E) CTNND1mRNA is strongly expressed in the epithelium of the developing tooth bud. (F) CTNND1 is expressed on
the dorsal epithelium of the palatal shelf (arrowhead) and in the epithelium of the tongue. (G) Expression is seen in the cardiomyocytes of the ventricular wall and the
interventricular septum and in the cells of the endocardium (arrowhead). Scale bars = 100 μm. Abbreviations: PA1, first pharyngeal arch; PA2, second pharyngeal arch;
PA3, third pharyngeal arch; Tg, trigeminal ganglion; Mx, maxillary process; Md, mandibular process; CN X, tenth cranial nerve; ULB, upper limb bud; S, somites; LLB,
lower limb bud; NP, nasal placode; H, heart, FNP, frontonasal process; Tb,mandibular tooth bud; PS, palatal shelf; T, tongue; IVS, interventricular septum; VW, ventricular
wall.
carried out mRNA in situ hybridization on human embryos using
a probe that binds to all four CTNND1 mRNA transcripts.
At Carnegie stage 13 (CS13), we found expression at multiple
sites within the developing head, including the frontonasal pro-
cesses, the forebrain,midbrain and rhombomeres (Fig. 4B and C).
Robust expression was also detected in the maxillary and
mandibular processes of the first pharyngeal arch (PA1), the
second and third pharyngeal arches (PA2 and PA3, respectively)
as well as in the proximal domains of the upper and lower
limb buds (Fig. 4A and B). Signal was also weakly detected
in the somites; however, strong expression was seen in the
developing heart, trigeminal ganglion and the 10th cranial nerve
(Fig. 4A and B).
By Carnegie stage 21, CTNND1 mRNA was expressed in the
brain (data not shown), tooth bud (Fig. 4E), the epithelial lining
of the tongue and oral cavity and in the tongue mesenchyme
(Fig. 4D). Expression was particularly strong in the intrinsic
muscles of the tongue: the superior longitudinal and transversal
muscles, and in the extrinsic genioglossus muscle (Fig. 4D).
Moreover, expression was evident in the dorsal epithelial lining
of the developing palatal shelves (Fig. 4F). In the heart, P120
expression was found in the cardiomyocytes of the ventricular
wall and interventricular septum, in addition to strong expres-
sion in the endocardium (Fig. 4G). Expression was also found
in the intrinsic epithelial lining of the stomach wall; both in the
pyloric part of the stomach and in the inner walls of the stomach
body, the pancreatic islets, the germinal center of the spleen, the
epithelial lining of the bladder, hindgut and in the spinal cord
and vertebral body (Supplementary Material, Figure S2).
Expression of phosphorylated p120-catenin predicts
fusion of the palatal seam
Because all of our participants had either cleft palate or
associated palatal anomalies, we also assessed p120-catenin
expression during palatal fusion in the mouse, which occurs
from embryonic day 12.5 (E12.5) to E15.5 (Fig. 5A–D). To examine
this, we used two antibodies recognizing phosphorylated
forms of p120-catenin: a tyrosine-phosphorylated form or
phosphorylation at serine 268 (pS-268), which is proposed to
trigger the disruption of epithelial cadherin-catenin complexes
(52,53). Neither of these forms of p120-catenin had been
previously analyzed in the palate. In palatal cross-sections
at E14.5, the medial epithelial seam (MES) is evident (Fig. 5B),
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followed a few hours later with dissolution of the seam at
E14.75 (Fig. 5C). While E-cadherin is expressed as expected
in the MES (54) (Fig. 5F and J), the two forms of p120-catenin
show very distinctive distributions. As the seam undergoes
EMT, at E14.5, pS-268 is strongly expressed as predicted in cell–
cell interfaces of the periderm layer along the medial seam,
clearly co-localising with E-cadherin (Fig. 5E and F). As the seam
degrades, E-cadherin expression is lost while p120-catenin
expression remains (Fig. 5G and H, white arrowheads). To our
surprise, we find phospho-tyrosine p120 staining in both the
mesenchymal and the epithelial cells, with a clear enrichment
marking the border between the epithelial and mesenchymal
populations (Fig. 5I and J, pink arrowheads). This distribution
appears unique to this stage of palate formation consistent with
reports that p120-catenin is tyrosine phosphorylate in an EGFR-
dependentmanner (55), and continues during the degradation of
the seam while E-cadherin expression decreases (Fig. 5K and L,
pink arrowheads). As a control, in earlier stages (E11–12.5), the
phospho-tyrosine expression is much lower and nearly identical
to the pS-268 staining (data not shown).
Heterozygous loss of p120-catenin leads to structural
changes in the laryngeal apparatus
Some of our participants presented with anomalies associated
with dysfunction of their velopharyngeal muscles and voice
irregularities (Supplementary Material, Table S1; Table 2), a
phenotype described in patients with VCF syndrome (56–58).
Antibody staining confirmed the presence of p120-catenin
protein during the development of the laryngeal and pharyngeal
tissues in the mouse (Supplementary Material, Figure S3A).
We then examined the laryngeal structures of mutant mice
compared with their littermate controls at E16.5, P1 and
P2.5 (Fig. 6). To do this, we crossed a mouse carrying the
ubiquitous β-actin::cre driver with Ctnnd1fl/f l mice in order
to generate heterozygous mutants (59,60) (Fig. 6C, H, M, R).
Because we previously showed that the vocal ligaments (VLs)
originated from the neural crest (61), we also generated
tissue-specific Ctnnd1 heterozygotes using the neural crest-
specific driver, Wnt1::cre (62) (Fig. 6E, J, O). We found identical
laryngeal anomalies in the heterozygous mutants in both
mouse crosses, confirming the neural crest-specificity of these
phenotypes.
Specifically, in control Ctnnd1fl/+ mice, the palatopharyngeus
(PLP) muscle, which elevates the larynx, is well defined and
runs uniformly perpendicular to the epiglottis thereby attaching
to the superior pharyngeal constrictor (SPC) muscle on either
side (Fig. 6A, B and D). On the other hand, the PLP and the SPC
were both severely disorganized in both sets of heterozygous
mice with an apparent increase in the cranio-caudal thickness
of the PLP muscle (Fig. 6C and E). Second, a striking phenotype
known as laryngeal webbing was observed (compare controls,
Fig. 6G, I, and Q, to mutants Fig. 6H, J, and R). Typically, the bilat-
eral vocal cords are parallel and meet at the midline (Fig. 6F–G,
with inset schematized and shown in Fig. 6P and Q). The outer
layer of the vocal fold ismade of an epithelium that encapsulates
the lamina propria comprising the VLs (Fig. 6P and Q). These
two layers function as the vibratory components for phonation
and oscillation. Instead, in heterozygous mutant mice, the VLs
show only a brief contact point between the opposing epithelia
(Fig. 6H, with inset schematized and shown in 6R and 6S). The
vocal cords are also thinner, lacking the lamina propria (Fig. 6R).
Laryngeal webbing was also seen in the Wnt1::cre heterozygotes
(Fig. 6J) compared with their littermate controls (Fig. 6I).
While the vestibular folds were well demarcated and the
ligaments within them clearly defined in controls (Fig. 6G),
the vestibular folds in the heterozygous mice were ectopically
fused and the ligaments sparse and dispersed (Fig. 6H). Caudally,
where the vestibular folds surrounded the normal corniculate
cartilage (COC) (Fig. 6K and L), the folds have separated in the
Ctnnd1 heterozygotes, albeit hypoplastic (Fig. 6M). Similarly,
the COC appeared hypoplastic and devoid of the underlying
lamina propria (Fig. 6M). Finally, in mutants, the muscles were
ectopically fused to the levator veli palatini muscles, which were
then fused to the cranial base (Fig. 6M). This, in turn, gave the
impression of a high-arched epiglottal area; a defect also found
in the Wnt1::cre heterozygous mutants (Fig. 6O).
We also explored other craniofacial phenotypes in our het-
erozygous mouse model. Compared with their littermate con-
trols (Supplementary Material, Figure S3B, a–e),mutantmice did
not show any cleft lip (Supplementary Material, Figure S3B, f),
face or limb dysmorphologies (Supplementary Material,
Figure S3B, f–h) or cleft palate (Supplementary Material, Figure
S3B, i) (n=12), consistentwith previous findings by Cox et al.This
was confirmed by micro-computed tomography (μCT) to check
for associated bony defects (n=6) (Supplementary Material,
Figure S3B, j).
P120-catenin isoform 1 function is required in multiple
organ systems
While the genetic mutation of p120-catenin in mouse models
revealed a role for the neural crest in oropharyngeal develop-
ment, analysis of multi-system involvement of p120-catenin
was difficult due to the embryonic lethality of the homozygous
null mice (5,9). We therefore turned to the frog Xenopus,
where in vivo function of p120-catenin has been well studied
(11,12,63). Previous analyses of p120-catenin requirements were
mainly performed with antisense morpholino oligonucleotide
knockdowns, which transiently prevent protein translation
(11). Instead, to create genetic mutants, we used CRISPR/Cas9
approaches, allowing us to specifically delete different p120-
catenin isoforms (64). As noted in the introduction, isoform
1 [full length at 968 amino acids (aa)] is most abundant
in mesenchymal cells, while isoform 3 (start at aa 102) is
preferentially expressed in epithelial cells (27–30). Isoforms 2
and 4, which start at 55 aa and 324 aa, respectively, are less well
characterized.
Embryos were injected at the one-cell stage with sgRNAs tar-
geting either of two coding exons, exon 3 or exon 7 (sgRNA1 and
sgRNA2 respectively, Fig. 7A). Disruptions in exon 3 are predicted
to only affect isoform 1, while sgRNA2 targeting exon 7 disrupts
all four isoforms.
When embryos were scored at gastrula stages following
sgRNA1 injections, disrupted or delayed blastopore closure
was evident (n=30/42 versus 2/30 in the controls) (Fig. 7B).
Furthermore, we noted severe early lethality (Fig. 7D), especially
using sgRNA2 which blocked all isoforms (Fig. 7D). Notably, by
neurula stages, the majority of these mutants died due to a loss
of integrity in the epithelium (data not shown).
Since the most well-established epithelial role for p120-
catenin is in complex with E-cadherin at cell–cell junctions, we
first examined E-cadherin localization in the neurectoderm at
stage 11, as gastrulation was concluding. Indeed, in uninjected
controls, high levels of p120-catenin and E-cadherin were found
co-localized at the cell interface (Fig. 7C, a–d). E-cadherin is
expressed throughout the cell membrane (Fig. 7C, b), whereas
p120-catenin, though localized to the cell membrane, appears
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Figure 5. Expression of phosphorylated p120-catenin predicts fusion of the palatal seam. (A–L) All images are coronal sections of CD1 wild-type murine embryos at
consecutive stages of palatal development. (A–D) H&E staining illustrates successive stages of palatogenesis from embryonic day (E) 12.5 to E15.5. (B) At E14.5, following
horizontal elevation, the opposing palatal shelves (blue arrows) meet and adhere to form the MES. (C) EMT occurs at E14.75 when the MES breaks down, forming
epithelial islands (blue arrowhead); the nasal and oral epithelial triangles form (yellow arrows). (D) At E15.5 palatal shelves are fused. Red box in (B) marks the regions
shown in (E, F, I and J). Red box in (C) marks the regions shown in (G, H, K and L). (E–L) Immunofluorescent staining for either pS-268 or p-tyrosine p120-catenin
antibodies (green) shown independently in (E, G, I and K), or in a merge with E-cadherin antibody staining (red) and DNA/DAPI stain (blue) (F, H, J and L). (E, F, I and J)
At E14.5, both forms of p120-catenin are expressed, with pS-268 strongly expressed in the periderm at the midline seam co-localizing with E-cadherin (E and F), while
p-tyrosine clearly enriched in the area marking the border between the epithelial and mesenchymal populations (I, J, pink arrowheads). (G, H, K and L) At E14.75, pS-268
p120-catenin is strongly expressed in the epithelial islands and the oral and nasal epithelial triangles; this is co-localised with E-cadherin during EMT and endocytosis,
while p120-catenin expression remains in some areas (H, white arrowheads). In contrast, p-tyrosine p120-catenin expression surrounds E-cadherin positive epithelial
islands, while E-cadherin expression has disappeared in the intervening mesenchymal cells (L, pink arrowheads). Scale bars = 50 μm. Abbreviations: T, tongue; PS,
palatal shelf.
distributed in puncta (Fig. 7C, a). Upon p120-catenin deletion,
the expression levels of endogenous E-cadherin in the epithelial
cells were diminished particularly at the interface between the
cells, leaving only the spot-like localization of both proteins at
the tricellular junctions of these epithelial cells (Fig. 7C, e–h). The
residual expression of p120-catenin may be due to the maternal
loading of the protein, as the CRISPRs should only affect zygotic
transcription, or due to the mosaicism of the CRISPR deletion.
As the sgRNA2 CRISPR was predicted to disrupt all four iso-
forms and led to severe lethality by neurula stages, the majority
of analyses were performed using the sgRNA1 CRISPR, which is
predicted to disrupt the predominantly mesenchymal isoform 1.
A proportion of the knockout animals survived past the neurula
stages, possibly due to mosaicism, and were examined at stage
46 to determine whether craniofacial and organ development
had occurred normally.We observed obvious craniofacial defects
in the CRISPR mutants, including a reduction in the width and
height of the head (Fig. 7E, l–n), a hypoplastic mouth opening
(Fig. 7E, m), delayed breakdown of the cement gland (Fig. 7E, l, m)
and heart and gut looping anomalies (Fig. 7E, n). Following on
from the disorganization of the laryngeal muscles seen in the
mouse mutants (Fig. 6), antibody staining against Pax2 was used
to label the muscle fibers while anti-collagen 2 (col2) antibody
labelled craniofacial cartilages in the mutants (Fig. 8A, a–h). In
control animals, the muscle fibers were well organised and
straight,while in themutants, themuscle morphology appeared
disorganized, particularly the rectus abdominus muscle, with
muscle striations being replaced by irregularly shaped fibers
(Fig. 8A, f, g). Consistent with previous observations (Fig. 7), cran-
iofacial cartilages were hypomorphic and compacted both in
the anterior-posterior and dorsal-ventral axes (Fig. 8A, a and
e). However, morphology of the chondrocytes appeared normal
(Fig. 8A, d, h).
Finally, since the participants (6/13) had a high frequency of
congenital heart defects and because p120 is strongly expressed
in the heart of human, mouse and frog embryos, we examined
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Figure 6. Heterozygous loss of p120-catenin leads to structural changes in the laryngeal apparatus. (A–O) Progression of the pharyngeal and laryngeal anomalies, (A, F
and K) Schematics show the organization of the wild-type oropharynx from the more rostral (A) to caudal (K) planes. H&E staining of coronal sections through control
(B, G, L: Ctnnd1fl/+) and heterozygous mutants (C, H, M: β-actin::cre/+; Ctnnd1fl/+) littermate at postnatal stage (P1). (B and C) The SPC (blue arrowhead) and PLP (red
arrowhead) in mutants are disorganized with an increased thickness in the PLP cranio-caudally (C) as compared with the controls (B). (G and H) The FVC (vestibular
folds) are well defined in the controls with abundant ligaments (G, red arrowhead). The FVC are fused in themutantmice (H, black arrowhead) with ill-defined vestibular
ligaments (H, red arrowhead). (L and M) The muscle attachments (blue arrowheads) superior to the FVC (black arrowhead) are well organized bilaterally in the controls
surrounding the COC (L). Caudally, when the FVC separated in the mutants, it appeared hypoplastic (black arrowhead) as did the COC. The muscles (blue arrowheads)
were ectopically fused to the LVP, producing an appearance of a ‘high-arched’ epiglottal area (M, orange hollow arrowhead). (D, E, I, J, N and O) Neural crest-specific
mutants showed comparable laryngeal phenotype. μCT soft tissue scans of E16.5 control (D, I, N: Ctnnd1fl/+) or neural-crest-specific (E, J, O: Wnt1::cre/+; Ctnnd1fl/+)
heterozygous mutant littermates. (D and E) Compare the PLP in control (D) to the very thick PLP muscle seen in mutant (E, red arrowheads). Compare the SPC in
control (D) to the disorganized and hypoplastic SPC muscles seen in mutants (E, blue arrowheads). (I and J) Laryngeal webbing was observed in mutant TVF (J, yellow
arrowhead) compared with parallel TVF in control littermate (I, yellow arrowhead). (N and O) Note aberrant muscle attachments (blue arrowheads) in (O) compared
with control (N). Control (N) epiglottal region compared with the high-arched epiglottal area observed in mutant littermate (O, orange hollow arrowhead). (P–S) The
laryngeal webbing phenotype. (P and S) Schematic representations of the wild-type (P) and mutant (S) anatomy at the vocal folds (TVF) from yellow-boxed insets in (G)
and (H), respectively. (Q and R) H&E staining of coronal sections through control (Q: Ctnnd1fl/+) and heterozygous mutant (R: β-actin::cre/+;Ctnnd1fl/+) littermate at P1.
(Q) In controls, well-defined VLs run parallel to the true vocal fold/cords (TVF). Underlying, the vocalis muscle (VM) and the thyroarytenoid muscle (TAM) are clearly
attached and well-organised. (R) Laryngeal webbing is seen in the heterozygous mutant mice, where the VLs accumulate at a thin contact point (black arrowhead), thus
perturbing the correct muscle attachments of the VM and TAM. Scale bars = 100 μm. Abbreviations: PLP, palatopharyngeus muscle; TAM, thyroarytenoid muscle; VM,
vocalis muscle; HB, hyoid bone; Epi, epiglottis; OB, occipital bone; LVP, levator veli palatini muscle; AEF, aryepiglottic fold; FVC, false vocal cord; CC, cricoid cartilage; TC,
thyroid cartilage; AC, arytenoid cartilage.
the hearts in the CRISPR-knockout tadpoles. Notably, the strong
expression of p120 seen in the different heart chambers in
the control tadpoles was lost when p120 was knocked down
(Fig. 8B, p). Themajority ofmutant tadpoles had heart anomalies
including heart-looping defects (Figs 7E, n and 8B, n). Notably, E-
cadherin is not expressed in the normal heart or the muscles
(Fig. 8B, I), suggesting that the heart andmuscle phenotypesmay
be manifestations of E-cadherin independent functions of p120.
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Figure 7. Ctnnd1 knockouts in Xenopus give rise to craniofacial and heart defects. (A) Embryos were injected at the one-cell stage with sgRNAs, sgRNA1 and sgRNA2
targeting exons 3 and 7, respectively. (B) Ventral view showing blastopores at stage 11. Embryos injected with sgRNA1 had delayed blastopore closure (bottom row)
compared to un-injected controls (UIC) (top row). The bar chart shows quantitation. Scale bars = 100 μm. (C) Confocal sections through the apical surface of ectodermal
cells at stage 11 of embryos injected with sgRNA1 (e–h) and UICs (a–d). (C) (a–d) p120-catenin (a, green) is expressed in puncta at the cell membranes. E-cadherin (b,
red) is expressed more evenly through the cell membranes. Both are colocalized at the cell–cell interface (c, d). Endogenous levels of p120-catenin and E-cadherin are
diminished at the cell–cell interface in the sgRNA1-injected embryos (e, f). Residual p120-catenin and E-cadherin are seen in a spot-like pattern, only at the tricellular
junctions (e–h, white arrowheads). (D) p120-catenin depletion led to lethality in embryos by the neurula stage. (E) Stage 46 tadpoles. (E) (i, l) Lateral views show a
flattened profile in p120 CRISPR tadpoles (l) compared with UICs (i). (E) (j, m) Frontal views showing a reduction in the size of mouth opening and a persistent cement
gland (white arrowhead) in p120 CRISPR tadpoles (m) compared with UICs (j). (E) (k, n) Ventral views showing a reduction in the size of craniofacial cartilages, altered
cardiac looping (black-dashed outline) and altered gut coiling (yellow arrowhead) in p120 CRISPR tadpoles (n) compared to UICs (k). Quantification of craniofacial defects
in UIC and p120 depleted tadpoles. Scale bars = 100 μm. ∗∗∗∗P<0.0001; ∗∗∗P< 0.001.
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Figure 8. Ctnnd1 knockouts in Xenopus give rise to altered morphogenesis of the muscles and heart. (A) Immunofluorescent staining for collagen 2 (col2, magenta),
muscle/pax2 (white) and nuclei (DAPI, blue); (a, anterior; p, posterior; d, dorsal; v, ventral). (A) (a, e) A lateral view of col2-positive branchial cartilages in UIC (a) and p120
CRISPR mutant (e) reveals the hypoplasia of mutant cartilages; however, cell morphology appears normal in p120 CRISPR mutants (h) (d and h, white arrowheads). (A)
(b, c, f and g) Pax2-expressing muscles revealed a defect in the fibril organization of the rectus abdominus muscle in the p120 CRISPR tadpoles (f, white arrowhead)
compared with the UICmuscles (b, white arrowhead); note insets in (c, g). (B) Ventral views of hearts of stage 46 tadpoles. Immunofluorescent staining for p120-catenin
(green), E-cadherin (red) and DNA (blue). (B) (i–m) Controls; (n–r) p120 CRISPRmutant tadpoles.Morphologic defects are evident in the size of the heart and directionality
of the loops (compare control heart (i) to mutant heart (n), yellow-dashed outlines). (B) (k, p) p120-catenin is strongly expressed in the heart of UIC tadpoles (k) but is
lost in p120 CRISPR tadpoles (p). (B) (l, q) Note the absence of E-cadherin in the control and mutant hearts. Scale bars = 100 μm.
Discussion
This work expands upon the spectrum of abnormalities
associated with CTNND1 variants beyond non-syndromic CLP
and BCD (1–3). Most notably, we describe in detail characteristic
craniofacial features including choanal atresia and unusual
patterns of hypodontia as well as heart, limb, laryngeal and
neurodevelopmental anomalies. We find the expression of
CTNND1 mRNA during the development of the pharyngeal
arches in human embryos, and we define the profile of two
phosphorylated forms of p120 in the mouse palate. Finally,
genetic approaches in mouse and Xenopus demonstrated novel
roles for CTNND1 in the oropharynx, craniofacial cartilages
and in the heart. Thus, our data implicate CTNND1 variants
as causative of a broad-spectrum syndrome that overlaps
with DiGeorge VCF syndrome as well as other disorders of
craniofacial development such as CHARGE and Burn McKeown
syndromes (65–68). All of these syndromes could be collectively
considered to be neurocristopathies. Notably, the neural crest-
specific disruption of CTNND1 in our animal models supports
this role for CTNND1 as a candidate neurocristopathy gene, and
we suggest that these newly identified variants likely highlight
both epithelial and mesenchymal roles for p120-catenin.
Prior to our study, the majority of the participants did
not have a recognizable or a diagnosed condition when
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they were recruited. Here, we demonstrate that they col-
lectively share consistent characteristic phenotypic features
that suggest that mutations in CTNND1 may lead to a much
broader phenotypic spectrum than previously described (1,2).
For instance, low set ears were reported in one case of
BCD by Kievit and colleagues (1); we find multiple partici-
pants with auricular anomalies particularly the low-set ears
and over-folded helices (Supplementary Material, Figure S1B;
Supplementary Material, Table S1). Similarly, syndactyly was
reported in one of the CTNND1 patients described in Ghoumid
et al. (2), and clinodactyly (one patient) and camptodactyly
(two patients) were reported by Kievit et al. (1). Again, we find
limb anomalies consistently associated with CTNND1 variation
(Supplementary Material, Figure S1C; Supplementary Material,
Table S1). The cardinal features of BCD include the ectropion
of the lower eyelids, euryblepharon and lagopthalmos (69,70);
these were not evident. However, five of our patients showed
other BCD-eyelid manifestations such as distichiasis and anky-
loblepharon (Supplementary Material, Table S1); we also found
short up-slanting palpebral fissures, hooded eyelids, high arched
eyebrows and telecanthus (Supplementary Material, Figure S1A;
Table 2 and Supplementary Material, Table S1). As BCD is
associated with both CTNND1 and CDH1 (E-cadherin) variants,
some of these phenotypes may represent the distinctive
functions of the E-cadherin-p120 complex; the majority of these
functions could be attributed to a role for the cadherin-catenin
in epithelia (71).
Of note, eight individuals had severe hypodontia, including
missing permanent canines and first permanent molars, even
in those without cleft lip/palate. Thus, missing canines and
molars could be classified as a microform cleft anomaly, espe-
cially when found in association with high-arched palate (72)
(Fig. 3I and K; Supplementary Material, Table S2).
Beyond the known phenotypes associated with CTNND1 and
CDH1, we note the novel phenotypes seen in our patients, which
include the heart anomalies and behavioral disorders. These
have not been reported previously in patients with a BCD diag-
nosis. Nevertheless, our findings suggest that both CTNND1
and CDH1 should be tested in patients with congenital orofa-
cial and cardiac anomalies. A key finding was choanal atre-
sia in four individuals; given the rarity of this anomaly, both
CTNND1 and CDH1 should be considered during genetic profiling
of patients with this anomaly, in addition to CHARGE and other
syndromes noted above. Indeed, Nishi et al. (73) reported cleft
lip, right choanal atresia, a congenital cardiac anomaly (tetralogy
of Fallot), agenesis of the corpus callosum, up-slanted palpebral
fissures and ear anomalies in a patient with CDH1 mutation;
however, at the time, this was not diagnosed as BCD.
While all of the variants found in the present study resulted
in the truncations of p120-catenin, they fell broadly into three
distinct groups: those falling within the N-terminal regulatory
region (p.Val148Aspfs∗24), those disrupting the armadillo repeat
region and presumably subsequent interactions with E-cadherin
(e.g. p.Arg461∗, p.Arg797∗, p.Leu494Argfs∗5 and p.GLy532Alafs∗6)
and those falling in the C-terminal domain (p.Ser868∗, the splice
variant c.2702-5A>Gandp.His913Profs∗3).Those falling in theN-
terminal region would be predicted to have the most complete
deletion and to best mimic a heterozygous loss of function sit-
uation. Indeed, similar to the heterozygous mice, these subjects
did not have cleft palate. Interestingly, those probands with C-
terminal truncations had the most complete cleft lip and palate
phenotypes. This was consistent with previous reports by Kievit
et al. (1), who reported a non-sense mutation (p.Trp830∗), and
Cox et al. (3), who reported p.Arg852∗ and a splice site mutation
(c.2417+G>T) (3). As these C-terminal truncations would all be
predicted to retain E-cadherin binding but lose crucial RhoGAP
interactions (24), one might hypothesize that a mutation in
this region prevents p120 clearing from the epithelial complex,
which is necessary for seam dissolution during palate closure.
Therefore, future analyses should focus on whether these C-
terminal truncations are acting in a dominant-negative manner,
and preventing clearance of E-cadherin from the seam. It would
also be useful to check whether any variants lead to non–sense-
mediated decay, especially those lying in the armadillo domain,
as Kievit and colleagues demonstrated (2).
With regards to non-epithelial functions of p120, some of
the phenotypes that this study, and others, has reported could
be explained by the known interactions of p120 in the Wnt
signalling pathway (20). Epithelial-specific knockouts of p120
(using a keratin-14 promoter) did not show tooth agenesis (10),
suggesting that the tooth anomalies in our patients do not arise
from the epithelial functions of p120. In support of this, two
key genes implicated in tooth agenesis are the Wnt ligand,
Wnt10A and a Wnt target gene Axin2 (74–84). The Wnt signalling
pathway may also explain the laryngeal findings (Fig. 6), as the
knockout of the Wnt transducer β-catenin is also known to lead
to similar vocal fold anomalies (85) as those seen in our neural
crest-specific p120-catenin heterozygotes (Fig. 6). Furthermore,
by targeting isoform 1, we should be losing the mesenchymal
form of p120 (Figs 7 and 8). These findings are consistent with
prior studies focused on neural crest, where the p120-catenin
association with Wnt signalling is well established (32,86,87).
Thus, we hypothesize that a subset of p120 phenotypes can also
be attributed to Wnt perturbation in the neural crest (Fig. 9).
The heart defects seen in our patients could also be attributed
to a failure in neural crest development, which is known to be
crucial for the development of the septum and valves (88–92).
Congenital heart disease (CHD) is the most common human
birth defect with an incidence that varies between 0.8 and 2%
in neonates (93,94). In addition, mild anomalies of the heart
may be undiagnosed. In contrast, we noted that nearly half
the subjects in our cohort have some form of CHD (6/13). Of
the CHD incidences seen in live births, phenotypes can range
from minor septal defects to severe malformations requiring
lifesaving surgical repair. A similar range of anomalies was
reflected across our cohort (Table 2). Furthermore, within fam-
ilies with single gene mutations, different types of structural
cardiac malformations may be observed (93,94). For example,
we observed this in Family A, where both mother and daughter
have septal defects but additional presentations vary (one has a
hypoplastic aortic arch andmitral valve stenosis while the other
has patent ductus arteriosus, Table 2). Thus, a thorough survey
of phenotypic variation and the inclusion of mild anomalies
is important for generating new hypotheses on key roles for
CTNND1 during human development. Future analysis will be
necessary to definitely determine functional relevance of the
different isoforms and the relationship with our novel patient
variants.
In addition to the phenotypes shared commonly across our
cohort, some participants in this study had scoliosis, and one
family reported two deceased children,who had bifid uvula, con-
genital cardiac disease (VSD,PDS), eye anomalies,developmental
delay and chronic bowel immotility and gastroesophageal reflux
disease; however, no genetic testing had been carried out. One
patient presented at a young agewith an ovarian dysgerminoma.
To our knowledge, this is the first patient with a CTNND1 variant
associated with an early onset cancer. Though p120 and E-
cadherin have been associated with cancer and tumourigenesis
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Figure 9. Model of CTNND1 function in systemic disease. (A) CTNND1mutations are not only implicated in conditions that affect epithelial structures but also systemic
conditions that originate frommesenchymal roles of p120-catenin. Structures in pink circles have been described in previous publications on CTNND1 (1,2); structures
in blue circles have been implicated previously in CTNND1-related disorders (1,2) and in this study. Structures in yellow circles have been identified in this study. (B)
BCD is primarily due to disturbances in E-cadherin/p120 interactions. The inclusion of other organ systems described here highlights the involvement of other known
molecular functions of p120, such as its role in the WNT signalling pathway and its interactions with Rho-GTPases, demonstrating its mesenchymal roles in producing
these systemic conditions.
(23–25,93–95), our data are insufficient to determine linkage in
this case. Nevertheless, future studies of genetic cancers should
consider E-cadherin/p120-catenin status as well.
Finally, a number of patients reported in DECIPHER have copy
number variants (CNVs) affecting CTNND1 (data not shown).
Previously published missense mutations are noted in Figure 1.
Interestingly, for CNVs, both deletions and duplications have
been associated with partially overlapping phenotypes. For
instance, two patients with a deletion of less than 4 MB had
anomalies including bulbous nose, limb anomalies, delayed
speech and language development, intellectual disability, nasal
speech, ventricular septal defect and cleft lip (data not shown).
Further studies will be necessary to understand the functional
consequences of these genetic changes.
In summary, we demonstrate that for the first time, p120
is not only involved in human conditions involving epithelial
integrity, most likely caused by aberrant E-cadherin/p120
interactions, but also in other important intracellular functions
(Fig. 9).We conclude that CTNND1-related disorders span a spec-
trum of phenotypes ranging from multi-system involvement to
non-syndromic clefting. While further studies will be necessary
to definitively understand the phenotype-genotype correlations,
CTNND1, and perhaps CDH1, should be considered when
patients present with characteristic craniofacial anomalies,
congenital cardiac defects and neurodevelopmental disorders.
Supplementary Material
Supplementary Material is available at HMG Online.
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